Gurunathan S, Sacks D L, Brown D R, Reiner S L, Charest H, Glaichenhaus N, Seder R A
Lymphokine Regulation Unit, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Exp Med. 1997 Oct 6;186(7):1137-47. doi: 10.1084/jem.186.7.1137.
To determine whether DNA immunization could elicit protective immunity to Leishmania major in susceptible BALB/c mice, cDNA for the cloned Leishmania antigen LACK was inserted into a euykaryotic expression vector downstream to the cytomegalovirus promoter. Susceptible BALB/c mice were then vaccinated subcutaneously with LACK DNA and challenged with L. major promastigotes. We compared the protective efficacy of LACK DNA vaccination with that of recombinant LACK protein in the presence or absence of recombinant interleukin (rIL)-12 protein. Protection induced by LACK DNA was similar to that achieved by LACK protein and rIL-12, but superior to LACK protein without rIL-12. The immunity conferred by LACK DNA was durable insofar as mice challenged 5 wk after vaccination were still protected, and the infection was controlled for at least 20 wk after challenge. In addition, the ability of mice to control infection at sites distant to the site of vaccination suggests that systemic protection was achieved by LACK DNA vaccination. The control of disease progression and parasitic burden in mice vaccinated with LACK DNA was associated with enhancement of antigen-specific interferon-gamma (IFN-gamma) production. Moreover, both the enhancement of IFN-gamma production and the protective immune response induced by LACK DNA vaccination was IL-12 dependent. Unexpectedly, depletion of CD8(+) T cells at the time of vaccination or infection also abolished the protective response induced by LACK DNA vaccination, suggesting a role for CD8(+) T cells in DNA vaccine induced protection to L. major. Thus, DNA immunization may offer an attractive alternative vaccination strategy against intracellular pathogens, as compared with conventional vaccination with antigens combined with adjuvants.
为了确定DNA免疫能否在易感性BALB/c小鼠中引发对硕大利什曼原虫的保护性免疫,将克隆的利什曼原虫抗原LACK的cDNA插入到巨细胞病毒启动子下游的真核表达载体中。然后将易感性BALB/c小鼠皮下接种LACK DNA,并以硕大利什曼原虫前鞭毛体进行攻击。我们比较了在有或无重组白细胞介素(rIL)-12蛋白存在的情况下,LACK DNA疫苗接种与重组LACK蛋白的保护效果。LACK DNA诱导的保护作用与LACK蛋白和rIL-12所达到的保护作用相似,但优于无rIL-12的LACK蛋白。LACK DNA赋予的免疫力是持久的,因为在接种疫苗5周后受到攻击的小鼠仍然受到保护,并且在攻击后感染被控制了至少20周。此外,小鼠在远离疫苗接种部位的位点控制感染的能力表明,LACK DNA疫苗接种实现了全身保护。接种LACK DNA的小鼠中疾病进展和寄生虫负荷的控制与抗原特异性干扰素-γ(IFN-γ)产生的增强有关。此外,LACK DNA疫苗接种诱导的IFN-γ产生增强和保护性免疫反应均依赖于IL-12。出乎意料的是,在接种疫苗或感染时CD8(+) T细胞的耗竭也消除了LACK DNA疫苗接种诱导的保护反应,表明CD8(+) T细胞在DNA疫苗诱导的针对硕大利什曼原虫的保护中发挥作用。因此,与用抗原结合佐剂进行的传统疫苗接种相比,DNA免疫可能为针对细胞内病原体提供一种有吸引力的替代疫苗接种策略。